PET Journal Club        Evan's  Home Page

Welcome (back) to the PET journal Club. Participation is open.


First floor R2 Bldg
Imaging Sciences Conference Room E124F
4 - 5:30 pm Thursdays

Thurs Mar 8, 2007
Yoder et al.  "Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study." ACER (In press)

Thurs Mar 1
Martinez et al. "Imaging human mesolimbic dopamine..." JCBFM 2003

previous papers

Berengere et al., "An improved version of the realistic digital brain phantom", Neuroimage 2006
Reilhac et al., "Creation and application of a simulated database..." IEEE TMI 2006


Smal et al., "PET of brain amyloid and tau in mild cogntiive impairment", NEJ Med 2007

Schiffer et al., "Therapeutic doese of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine", Synapse 2006.

Christian et al., "Measuring dopamine neuromodulation in the thalamus: using [F-18]fallypride...", Neuroimage 2006.

Price et al., "Kinetic modeling of amyloid binding in humans using PET...", JCBFM 2005.


Further in the past:

Thurs June 1
Gunn et al. NeuroImage 1997 SRTM via basis function technique.


Thurs May 4
read this one first
Kamakura et al. JCBF 2005. PET studies of net blood-brain clearance of FDOPA to human brain:age dependent decline of 1Fflourodopamine storage capacity.

then read...
the top secret manuscript - see email from me - please do NOT distribute.


Thurs Mar 30
Cunningham et al JCBF  1993 Spectral Analysis of PET data (paper handed out last week - as Cristian for copy)

Marenco et al. PET imaging of DA release after nicotine.


Thurs Mar 23

Modeling of PIB compound. Price et al JCBF 2005

Effect of naltrexone on alcohol-induced changes in Rat central DA-ergic system. Lee et al. Alcohol and Alcoholism 2005


Thurs Mar 16   (spring break - no papers)


Thurs Mar 9
Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?
Egli. Addiction Biology Dec 2005


Altered prefrontal dopaminergic function in chronic recreational ketamine users
Narendran et al. Am J Psychiatry 2005


Thurs Mar 2

The acute anti-craving effect of acomproistate in alcohol preferring rats is associated with modulation of the mesolimbic dopamine system/
Cowen et al. Addiction Biology  2005

Thurs  Feb  23 - skipped for meeting with TK Li

Thurs Feb 16, 2006

Two papers on deriving blood input functions from PET images of rats.  We -and others- have fund it difficult to take blood samples. Minimally Invasive Method of Determining Blood Input Function from PET Images in Rodents
Joonyoung Kim, PhD; Pilar Herrero, MS; Terry Sharp, RT; Richard Laforest, PhD; Douglas J. Rowland, PhD; Yuan-Chuan Tai, PhD; Jason S. Lewis, PhD; and Michael J. Welch, PhD

Non-invasive quantification of cerebral blood flow for rats by microPET imaging of 15O labelled water: the application of a cardiac timeactivity curve for the tracer arterial input function.   Yee, Seong-Hwan; Jerabek, Paul A.; Fox, Peter T. Nuclear Med Comm 2005.
(I need to get the file with pictures. You can dounload it by going to the journal through IUSOM online journals)


Thurs Feb 9, 2006

Comparison of different weighted objective functions for fitting models to PET data, Muzic and Christian, 2006 Medical Physics
(you may not be able to save it but you should be able to print it.)
If the Muzic and Christian paper is not your cup of tea, lets try another one too - see this space soon:
Brooks et al. Brain 2003 Finger Tapping in normals and PD with PET, raclopride
___________________________________________________________________________________

Thurs Feb 2, 2006
Rouze et al., Design of the IndyPET II small animal scanner

Rouze et al. Design of the ISAP scanner with 1 microliter resolution.

(extra paper: Initial Evaluation of ISAP, Rouze et al. 2005)


Thurs Jan 26, 2006
Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain Hideo Tsukada et al. Brain Research (1999)

Thurs Jan 19, 2006.
Assessment of methylphenidate-induced changes in binding of continuously infused [11C]-raclopride in healthy human subjects: correlation with subjective effects.  
J. I. Udo de Haes  et al. Psychopharmacology (2005).

Other

Friday Dec 2, 2005
recent paper by Cristian Heidebreder et al.  "phMRI" does not track with dopamine or CBF
paper by Nanette Freedman: SUV does not track with the Patlak K as a measure of disease progression (argument FOR parameter estimation)


Future:

MAP-based kinetic analysis for voxel-by-voxel compartment model estimation: Detailed imaging of the cerebral glucose metabolism using FDG
Yuichi Kimura et al NeuroImage 2005




Past:

Friday Nov 18, 2005  (tentative time: 2PM)
Mass effect of injected dose in small rodent imaging by SPECT and PET, Kung and Kung, 2005.
Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release, Olive et al 2001

Friday Nov 11

Dynamic PET Data Analysis,  Maxoyer, Huesman, Budinger, Knittel.  JCAT 1986 10(4) 645-653


Thurs Sept 15 - 10am

Endres et al. 2003 Carfentanil modeling by various reference region methods
Rubin et al . 2001 Rat Head Holder Evaluation



Thurs Aug 25 - 10 am.
(we will try to discuss 3 short papers.)

Serotonin 1a is reduced in Panic Disorder
Serotonin 1a is not changed in PTSD
Serotonin 1a in depression


Ancient history of the PET journal club

Wed Aug 21 2002, 4 pm
This recent NeuroImage paper by Pappata et al. in Orsay is a very exciting twist on a new application of PET for detection of NEUROTRANSMITTER
activation in a single subject in a single scanning session.  "In Vivo detection of striatal dopamine release during reward ..."
Briefly: Their model assumes that time-activity curves measured by PET during the performance of a task -purported to raise dopamine levels-
can be described by a linear combination of a few temporal copmonents (think of them as basis functions). These temporal components
are chosen based on simulations of 11C-raclopride uptake with and without dopamine and/or blood flow changes at the time of the task.
If they estimate the coefficient of the basis function describing deflections in the time curve due to DA changes to be nonzero, they consider
that to be an indication of DA activation.  The strength of the activation is related to the significance of the t-test comparing the coefficient
and zero (null hypothesis.)
Interesting points to watch for
1. Is it plausible that dopamine activates only for unexpected (R-) reward and not expected reward?
2. Can we really describe the response of the PET curve to DA as a LINEAR model?  After all, the
model that they (we all) use to describe raclopride competition with dopamine is NONLINEAR.
3.  Note their comment that they are HIGHLY sensitive to motion artifacts.
4.  For members of the Summer Image Registration Course - note their rejection of the mutual information
algorithm for motion correction.
5.  For those of you who liked Sweeney Todd, note the reference to the paper by Fried, 2001:
Microdialysis in people!!!!



Previous papers:

Thurs May 2, 2002

I will give a brief introduction to multiple-injection ligand studies with PET for the purpose of getting precise estimates of B'max, the number of available receptors.
Lets use two of my papers as introductory reading
Synapse, 1996
Synapse, 1999
Note.  This method was pioneered by Jacques Delforge of the PET group in Orsay. (But with short notice, I have my papers digitized and NOT
his - so we can start here at least.)

The 1996 paper is an investigation with your favorite DA ligand, CFT, to estimate number of Dopamine transporters in the striatum of monkeys before and after MPTP as a model of Parkinson's.
The 1999 paper is a letter defending the 1996 paper AND giving a succinct explanation of why the multiple-injection scheme is valid - and preferable to other methods (complexity notwithstanding.)

These papers - coa-authored by myself and Brad Christian, PhD, among others, will serve as  a good intro to Dr Christian's talk the next day in the same room


Wed December 19, 2001

Lets look into Partial Volume Effects and PV Correction methods.

 Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ.  Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects.J Cereb Blood Flow Metab 1992 Jul;12(4):571-83

This is a classic PET paper which was the first (?) to offer a pixel-by-pixel method for correcting images for the partial volume effect.The method uses information from MRI images. It segments the MR into different tissue types; creates simulated PET images for a given 'true' concentration for each tissue type assuming uniformity within a tissue type and then 'overlays' the simulated PET for each type to build up a simulated PET image of the brain.  Doing this multiple times establishes a relationship between true concentration and measured (in the simulated) concentration. This relationship is the basis for correcting real images back to their 'true' concentrations.
and then lets see how the theory affects some data: perhaps a blood flow application...
Meltzer CC, Cantwell MN, Greer PJ, Ben-Eliezer D, Smith G, Frank G, Kaye WH, Houck PR, Price JC.
 Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med. 2000 Nov;41(11):1842-8.
 

Wed. Nov 14, 2001
Koeppe RA, Holthoff VA, Frey KA, Kilbourn MR, Kuhl DE (1991): Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate   and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735-744.
This paper goes to what are we measuring when we measure DV'' - that's the so called Vdi image!

Ilgin et a.l Neurology (1999), 52:1221-1226.. PET imaging of Dopamine Transporter in progressive supranuclear palsy and Parkinson's disease.
This paper is from competitors to our own Allison Brashear, MD - We must understand our enemy to vanquish them!


Wed. Oct 17:
Simplified Reference Tissue Model for PET Receptor Studies.  A. Lammerstma and S Hume. NeuroImage (1996), 4:153-158.
This is one popular way to make Binding Potential estimates/images in the ABSENCE of blood data. But it comes with its share
of assumptions.

The above paper is based on this earlier reference region paper:  I will try to scan it for on-line access, otherwise, you'll need to come to my
office to copy it.  But its a really good discussion of what it means when the reference region is not perfect (ie devoid of receptors) and what assumptions must be satisfied to use a reference region model.

Compartmental Analysis of Diprenorphine Binding to Opiate Receptors in the Rat In Vivo and Its Comparison with Equilibrium data.
Cunningham, Hume et al., J Cereb Blood Flow and Metab, (1991), 11: 1-9.



 

Wed Oct 3,2001
Modulatory effects of L-DOPA on D2 dopmamine receptors in rat striatum, measured using in vivo microdialysis and PET. Opacka-Juffry et al. J Neural Transm (1998) 105: 349-364.

Preview:  This paper has microdialysis, PET, raclopride, Parkinsons, DOPA, Dopamine, small animals --- it has it al!  Come hear why QUANTITATIVE imaging in small animal PET is not straightforward.
Evan's Cliff notes:

Figure 1. demonstrates a crucial bias in BP measurements from PET data when the dose of cold carrier (i.e., unlabeled) ligand is too high. The question becomes, Can it be corrected? If not, we can't compare results across studies if the mass dose is greater than the threshold value at which measured BP drops off. (see below)
....................................|
...................................V

Equation 1:  BP = [appBmax/{Mass dose + appKD}] + NS describes Figures 1 and 2. But is it correct? Where does it come from? Does it make sense that Binding Potential should be non-zero at very large mass doses? I don't think so!  I think the form of the model should be simply: BP = B / [K + M] . Although, I know that such a functional form would have difficulty fititng  the points at 5000 nmol/kg in the Fig, above.

Figure 3. demonstrates the time course of dopamine response to a pharmacological stimulation.  This one presumably involves synthesis is thus would be expected to be slower than simply "release". Nevertheless, it is relevant to anyone hoping to image DA changes.

Reminder:
 1 Curie = 37 GBq
so a specific activity of 37GBq/umol = 1Ci/umol = 1000mCi/umol (a decent SA for 11C-raclopride)

Interesting: Here's what happens if we merge data from 2 different studies of BP vs mass by the Hammersmith group.




Sept. 12
Koepp et al, Nature vol 393, 1998, "Evidence for Striatal Dopamine Release During a Video Game"
 

Possile Future Papers:

Perhaps we will look at blood flow models in late Dec or early Jan.  Stay tuned!
 



Back to Evan's Home Page